Alkermes plc (ALKS)

NASDAQ: ALKS · Real-Time Price · USD
26.97
-0.74 (-2.67%)
At close: Sep 12, 2025, 4:00 PM EDT
27.02
+0.05 (0.17%)
After-hours: Sep 12, 2025, 6:24 PM EDT
-2.67%
Market Cap4.45B
Revenue (ttm)1.51B
Net Income (ttm)348.45M
Shares Out 165.08M
EPS (ttm)2.08
PE Ratio12.99
Forward PE20.26
Dividendn/a
Ex-Dividend Daten/a
Volume2,480,907
Open27.44
Previous Close27.71
Day's Range26.93 - 27.68
52-Week Range25.17 - 36.45
Beta0.49
AnalystsStrong Buy
Price Target41.29 (+53.1%)
Earnings DateOct 23, 2025

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable su... [Read more]

Sector Healthcare
IPO Date Jul 16, 1991
Employees 1,800
Stock Exchange NASDAQ
Ticker Symbol ALKS
Full Company Profile

Financial Performance

In 2024, Alkermes's revenue was $1.56 billion, a decrease of -6.36% compared to the previous year's $1.66 billion. Earnings were $367.07 million, an increase of 3.18%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for ALKS stock is "Strong Buy." The 12-month stock price target is $41.29, which is an increase of 53.10% from the latest price.

Price Target
$41.29
(53.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alkermes Appoints Joshua Reed as Chief Financial Officer

DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.

1 day ago - PRNewsWire

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program

— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/o...

2 days ago - PRNewsWire

Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)

Alkermes plc (NASDAQ:ALKS) World Sleep Congress 2025 Conference September 8, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Rich...

5 days ago - Seeking Alpha

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Ali...

5 days ago - PRNewsWire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025

– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity,...

19 days ago - PRNewsWire

Alkermes: A More Than Solid Quarter

Alkermes plc is a mid-cap and quite profitable commercial-stage biopharma company, and we are revisiting it today for the first time in a year. The company just reported Q2 financial results, with pro...

6 weeks ago - Seeking Alpha

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q2 2025 Earnings Call July 29, 2025 8:00 AM ET Company Participants Blair C. Jackson - Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO C.

6 weeks ago - Seeking Alpha

Alkermes plc Reports Second Quarter 2025 Financial Results

—    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkerme...

6 weeks ago - PRNewsWire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton De...

7 weeks ago - PRNewsWire

Alkermes to Report Second Quarter Financial Results on July 29, 2025

DUBLIN , July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

2 months ago - PRNewsWire

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Co...

3 months ago - PRNewsWire

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ -- Alker...

3 months ago - PRNewsWire

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible

The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on...

4 months ago - Seeking Alpha

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops - ...

4 months ago - Seeking Alpha

Alkermes plc Reports First Quarter 2025 Financial Results

—    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN , May ...

4 months ago - PRNewsWire

New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD)

– Survey Respondents Reported That AUD Diagnosis and Decision to Seek Treatment Were Driven by Negative Consequences of Drinking – – Respondents Cited the Influence of Their Healthcare Providers and t...

4 months ago - PRNewsWire

Alkermes to Report First Quarter Financial Results on May 1, 2025

DUBLIN , April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

5 months ago - PRNewsWire

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake ...

5 months ago - PRNewsWire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia

DUBLIN , April 1, 2025 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to p...

5 months ago - PRNewsWire

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

– Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' E...

6 months ago - PRNewsWire

Alkermes to Participate in Upcoming Investor Conferences

DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in webcast fireside chats at two upcoming investor conferences. TD Cowen 45th Annual...

7 months ago - PRNewsWire

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

7 months ago - Seeking Alpha

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard...

7 months ago - Seeking Alpha

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025

—    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — —    GAAP Net Income from Continuing Operations of $372 Million and Diluted...

7 months ago - PRNewsWire

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.

7 months ago - PRNewsWire